{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:54:34Z","timestamp":1791554074955,"version":"4.3.4"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","award":["AI116420"],"award-info":[{"award-number":["AI116420"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","award":["AI125770"],"award-info":[{"award-number":["AI125770"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Veterans Affairs","award":["IK6 BX005386"],"award-info":[{"award-number":["IK6 BX005386"]}],"id":[{"id":"https:\/\/ror.org\/05rsv9s98","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["mBio"],"published-print":{"date-parts":[[2024,8,14]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Invasive fungal infections (IFIs) caused by pathogenic fungi pose a significant public health concern, particularly for immunocompromised individuals. Mortality rates for IFIs remain high, and currently available treatment options are limited. Existing antifungal agents often suffer from limited clinical efficacy, poor fungicidal activity within the host, potential toxicity, and increasing ineffectiveness due to emerging resistance, especially against triazole drugs, the current mainstay of antifungal treatment. A recent study has identified MBX-7591, a small molecule with promising antifungal activity against\n                      <jats:italic toggle=\"yes\">Aspergillus fumigatus<\/jats:italic>\n                      and other pathogenic fungi, including strains resistant to triazoles (C. Gutierrez-Perez, C. Puerner, J. T. Jones, S. Vellanki, E. M. Vesely, et al., mBio e01166-24, 2024,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.1128\/mbio.01166-24\" xlink:type=\"simple\">https:\/\/doi.org\/10.1128\/mbio.01166-24<\/jats:ext-link>\n                      ). This novel compound appears to inhibit stearoyl-CoA 9-desaturase, a key enzyme involved in fungal fatty acid biosynthesis. By disrupting the conversion of saturated fatty acids to oleic acid, MBX-7591 offers a unique mechanism of action, potentially reducing the risk of resistance development. Here, we now discuss the implications of these groundbreaking findings for overcoming antifungal drug resistance.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/mbio.01361-24","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T09:19:41Z","timestamp":1720689581000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["MBX-7591: a promising drug candidate against drug-resistant fungal infections"],"prefix":"10.1128","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0901-6909","authenticated-orcid":false,"given":"Nivea","family":"Pereira de Sa","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Stony Brook University","place":["Stony Brook, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8418-3120","authenticated-orcid":true,"given":"Maurizio","family":"Del Poeta","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Stony Brook University","place":["Stony Brook, USA"]},{"name":"Veterans Administration Medical Center","place":["Northport, USA"]},{"name":"Institute of Chemical Biology and Drug Discovery, Stony Brook University","place":["Stony Brook, USA"]},{"name":"MicroRid Technologies Inc.","place":["Dix Hills, USA"]},{"name":"Division of Infectious Diseases, School of Medicine, Stony Brook University","place":["Stony Brook, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00103-8"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004404"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.939088"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15591"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2005.06.017"},{"key":"e_1_3_2_8_2","unstructured":"WHO fungal priority pathogens list to guide research development and public health action. 2022. World Health Organization:Geneva"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00437-19"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/499819"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2019.02.008"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy859"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48029-2"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00316-10"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2410.180730"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01166-24"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.00092"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004487"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006096"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005775"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2021.11.033"}],"container-title":["mBio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mbio.01361-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mbio.01361-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:37:53Z","timestamp":1791553073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/mbio.01361-24"}},"subtitle":[],"editor":[{"given":"Joseph","family":"Heitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,14]]}},"alternative-id":["10.1128\/mbio.01361-24"],"URL":"https:\/\/doi.org\/10.1128\/mbio.01361-24","relation":{},"ISSN":["2150-7511"],"issn-type":[{"value":"2150-7511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"2024-07-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01361-24"}}